- Home
- ZH vs ZURA Comparison
ZH vs ZURA Comparison
Compare ZH & ZURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ZH | ZURA |
|---|---|---|
| Founded | 2011 | 2022 |
| Country | China | United States |
| Employees | N/A | 30 |
| Industry | Business Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 293.3M | 435.0M |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | ZH | ZURA |
|---|---|---|
| Price | $3.22 | $6.90 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $11.78 |
| AVG Volume (30 Days) | 299.6K | ★ 465.7K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $20.74 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.23 | $0.99 |
| 52 Week High | $5.87 | $7.19 |
Technical Indicators
Market Signals| Indicator | ZH | ZURA |
|---|---|---|
| Relative Strength Index (RSI) | 35.45 | 60.97 |
| Support Level | N/A | $5.62 |
| Resistance Level | $4.20 | $6.76 |
| Average True Range (ATR) | 0.14 | 0.44 |
| MACD | -0.03 | -0.00 |
| Stochastic Oscillator | 1.75 | 68.09 |
Price Performance
Historical ComparisonAbout ZH Zhihu Inc. (every two of each representing one ordinary share)
Zhihu Inc is predominantly engaged in the operation of one online content community and monetizes through paid membership services, advertising services, content-commerce solutions services, and vocational training in China. It generates revenues from Advertising services, Paid membership services, Content-commerce solutions, and Others. It derives all its revenues within China.
About ZURA Zura Bio Limited
Zura Bio Ltd is a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases. It is developing three assets which have completed Phase I/Ib studies and are Phase II ready. It is developing a portfolio of therapeutic indications for tibulizumab and torudokimab with a goal of demonstrating their efficacy, safety, and dosing convenience in autoimmune and inflammatory diseases.